George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlpha Growth Regulatory News (ALGW)

Share Price Information for Alpha Growth (ALGW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.20
Bid: 1.10
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.20 (18.182%)
Open: 1.20
High: 1.20
Low: 1.20
Prev. Close: 1.20
ALGW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Release of 2021 Annual Report

31 May 2022 07:00

RNS Number : 2821N
Alpha Growth PLC
31 May 2022
 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as in force in the United Kingdom pursuant to the European Union (Withdrawal) Act 2018). Upon the publication of this announcement, this inside information is now considered to be in the public domain

 

Alpha Growth Plc

("Alpha", or the "Company")

 

Release of 2021 Annual Report

 

Alpha Growth Plc (LSE: ALGW and OTCQB: ALPGF), a leading financial services specialist in the growing life insurance linked longevity asset class, is pleased to announce the release of its Annual Report & Financial Statements for the sixteen months ended 31 December 2021 (the '2021 Annual Report'). The sixteen-month period is the result of aligning the year end reporting of all group companies. The 2021 Annual Report is available at www.algwplc.com.

 

During this period, the Company made significant investments into its various strategies, which included the announced acquisition of Providence Life and Assurance Company, a Bermudan life assurance company with over £225 million of gross assets. This acquisition, together with continued subscriptions into the BlackOak Alpha Growth Fund, has led to a significant increase in revenue to £2,645,172 for the period ending 31 December 2021 vs £81,592 for 2020. The increased investments, which included acquisition costs and expansion of Providence's operations, and marketing for the BlackOak Alpha Growth Fund, resulted in a loss for the sixteen-month period of £1,666,304 vs £567,200 for 2020.

 

Despite the loss, the Company achieved net cash inflow for the sixteen months to 31 December 2021 of £151,903 vs 2020 outflow of £130,321. The Group anticipates to be break even on an operating profits basis by the end of 2022. The Company does not envisage a fundraise, given the number of outstanding warrants available, as well as the supportive nature of those holding the warrants.

 

The Company plans to modestly increase head count at the subsidiary level and maintain the current level of executives, with the possibility of adding an additional director. Given the achievements of the past sixteen months, the Directors were awarded outstanding options in line with the arrangements set out in the IPO prospectus of the Company. The options are for five years, with an exercise price of 2.95p.

 

For 2022, we continue with our 2B plan as previously announced - the 2B plan is Alpha Growth's strategy of achieving $2bn AUM by 2025. This strategy includes expanding our activities within the life insurance business and continuing with the growth of BlackOak Alpha Growth Fund. Part of the expansion includes the previously announced acquisition of a Guernsey insurance company which is expected to complete in the next quarter, and which will accrete significant assets under management and is also expected to contribute to revenue and profits, whilst our head office costs will only increase marginally.

 

Gobind Sahney, Executive Chairman commented, "This report covers a transformation period for Alpha Growth and one which has seen tremendous growth of AUM and its associated revenue, it's also seen us complete on one significant acquisition within the insurance space and sign a share purchase agreement for another - with only regulatory approval to be given.

 

We are ahead of schedule with our 2B plan and will update the market when appropriate, as we progress towards our $2bn AUM target we will once again see revenue increase significantly. Our annual general meeting is scheduled for June 20th and I look forward to discussing this report further, and the progress we're making at Alpha Growth."

 

The 2021 Annual Report will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

For more information, please visit www.algwplc.com or contact the following:

 

Alpha Growth Plc

+44 (0) 20 3959 8600

Gobind Sahney, Executive Chairman 

info@algwplc.com

Arden Partners plc

+44 (0) 20 7614 5900

Ruari McGirr / Alexandra Campbell-Harris (Corporate Finance)

UK Investor Relations - Mark Treharne

ir@algwplc.com

 

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of life insurance linked longevity assets. Building on its well-established network, the Alpha Growth Group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The Group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

 

Longevity Assets and Non-correlation

As a longevity asset, it is non-correlated to the real estate, equity capital and commodity markets. Its value is a function of time because as time passes the value gets closer to the face value of the policy. Hence creating a steady increase in the net asset value of the investment. This makes it highly attractive to investors wishing to counteract volatility within an investment portfolio and add yield.

 

Note: The Company only advises on and manages Longevity Assets that originate in the USA where the structured and life settlement market is highly regulated.

 

Forward Looking Statements Disclaimer

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward- looking statements, which speak only as of the date of this document. Readers should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences, including the merits of information and the risks. Readers of this announcement are advised to conduct their own due diligence and agree to be bound by the limitations of this disclaimer.

 

Important Notice

The content of this announcement has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (FSMA). This announcement has been issued by and is the sole responsibility of the Company. The information in this announcement is subject to change.

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSXBLFXLELZBBV
Date   Source Headline
22nd Dec 20239:00 amRNSExpiration of Warrants
13th Dec 20237:00 amRNSAlpha International Life Receives KBRA Rating
14th Nov 20233:36 pmRNSJason Sutherland Receives Industry Recognition
9th Oct 20234:00 pmRNSHolding(s) in Company
9th Oct 20232:43 pmRNSHolding(s) in Company
29th Sep 202311:00 amRNSHalf-year Report
14th Aug 20236:29 pmRNSHolding(s) in Company
19th Jun 20237:00 amRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM
15th May 20237:00 amRNSAcquisition of Minority Holding and Share Issuance
3rd May 20237:00 amRNSHolding(s) in Company
2nd May 20237:00 amRNS2022 Annual Report & Financial Statements
15th Mar 20237:00 amRNSWarrant Exercise and Total Voting Rights
6th Mar 20237:00 amRNS2022 Annual Recap and Fund Results
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20231:10 pmRNSHolding(s) in Company
20th Jan 20232:05 pmRNSSecond Price Monitoring Extn
20th Jan 20232:00 pmRNSPrice Monitoring Extension
20th Jan 202311:05 amRNSSecond Price Monitoring Extn
20th Jan 202311:00 amRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSFurther Regarding Havelet Acquisition
6th Dec 20227:00 amRNSCompletion of Share Purchase Acquisition
17th Nov 20227:00 amRNSFinancial Services Company Acquistion
27th Oct 20227:00 amRNSChange of Adviser
26th Oct 20224:41 pmRNSSecond Price Monitoring Extn
26th Oct 20224:36 pmRNSPrice Monitoring Extension
3rd Oct 20224:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20224:35 pmRNSPrice Monitoring Extension
3rd Oct 20222:06 pmRNSSecond Price Monitoring Extn
3rd Oct 20222:00 pmRNSPrice Monitoring Extension
3rd Oct 202211:06 amRNSSecond Price Monitoring Extn
3rd Oct 202211:01 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
28th Sep 20227:00 amRNSAppointment as Investment Manager/Insurance Update
12th Sep 20222:06 pmRNSSecond Price Monitoring Extn
12th Sep 20222:00 pmRNSPrice Monitoring Extension
9th Sep 20222:06 pmRNSSecond Price Monitoring Extn
9th Sep 20222:00 pmRNSPrice Monitoring Extension
8th Sep 20227:00 amRNSDirector and Personnel Announcement
3rd Aug 20227:00 amRNSHolding(s) in Company
26th Jul 20224:40 pmRNSSecond Price Monitoring Extn
26th Jul 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20224:03 pmRNSResults of the Annual General Meeting
31st May 20227:00 amRNSRelease of 2021 Annual Report
27th Apr 20227:00 amRNSShareholder Information Update
24th Mar 20224:41 pmRNSSecond Price Monitoring Extn
24th Mar 20224:36 pmRNSPrice Monitoring Extension
24th Mar 20222:05 pmRNSSecond Price Monitoring Extn
24th Mar 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.